SCG2 and in situ carcinoma: In the same year, an assessment from Italy found that secretogranin II and protein 7B2 were upregulated in RRMS patients compared to progressive MS patients, while fibrinogen and fibrinopeptide A were downregulated in CIS compared to progressive MS.